PDL BioPharma, Inc. (NASDAQ:PDLI) has been given an average recommendation of “Buy” by the six research firms that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $3.50.

PDLI has been the subject of a number of recent research reports. Zacks Investment Research raised PDL BioPharma from a “sell” rating to a “hold” rating in a report on Monday, May 15th. BidaskClub cut PDL BioPharma from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 11th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $4.00 target price on shares of PDL BioPharma in a report on Thursday, August 10th. ValuEngine raised PDL BioPharma from a “hold” rating to a “buy” rating in a report on Friday, August 4th. Finally, Cowen and Company reaffirmed a “hold” rating on shares of PDL BioPharma in a report on Wednesday, May 3rd.

TRADEMARK VIOLATION NOTICE: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.watchlistnews.com/pdl-biopharma-inc-pdli-receives-average-rating-of-buy-from-analysts/1532069.html.

Several large investors have recently modified their holdings of PDLI. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of PDL BioPharma by 43.8% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 45,948 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 14,000 shares during the last quarter. Airain ltd bought a new stake in shares of PDL BioPharma during the first quarter valued at $107,000. KBC Group NV bought a new stake in shares of PDL BioPharma during the first quarter valued at $107,000. Credit Agricole S A boosted its stake in shares of PDL BioPharma by 34.9% in the first quarter. Credit Agricole S A now owns 50,000 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 12,942 shares during the last quarter. Finally, Public Employees Retirement System of Ohio boosted its stake in shares of PDL BioPharma by 15.3% in the first quarter. Public Employees Retirement System of Ohio now owns 55,423 shares of the biotechnology company’s stock valued at $126,000 after buying an additional 7,336 shares during the last quarter. 83.35% of the stock is owned by institutional investors.

PDL BioPharma (NASDAQ PDLI) traded up 4.08% during midday trading on Wednesday, reaching $3.06. 585,330 shares of the company traded hands. The company has a 50-day moving average price of $2.52 and a 200-day moving average price of $2.33. PDL BioPharma has a 12-month low of $1.93 and a 12-month high of $3.77. The company has a market cap of $471.48 million, a price-to-earnings ratio of 7.03 and a beta of 0.58.

PDL BioPharma (NASDAQ:PDLI) last issued its earnings results on Thursday, August 3rd. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.17. PDL BioPharma had a return on equity of 9.07% and a net margin of 23.03%. The business had revenue of $143.80 million during the quarter, compared to analysts’ expectations of $56.30 million. During the same quarter in the prior year, the firm earned $0.09 EPS. The business’s revenue for the quarter was up 584.8% compared to the same quarter last year. On average, analysts predict that PDL BioPharma will post $0.61 earnings per share for the current fiscal year.

PDL BioPharma Company Profile

PDL BioPharma, Inc seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company’s segments include income generating assets and product sales.

Receive News & Ratings for PDL BioPharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.